What it's for (Indications)
- Danazol, a synthetic androgen, is primarily indicated for the management of specific conditions in which its unique hormonal and antigonadotropic properties provide therapeutic benefit.
- Its use is generally reserved for severe cases or when other treatment modalities are ineffective or contraindicated.
- Key indications include: 1.
- **Endometriosis:** Danazol is utilized in the treatment of endometriosis, a chronic gynecological condition characterized by the presence of endometrial-like tissue outside the uterus.
- It helps alleviate associated pain symptoms (e.
- g.
- , dysmenorrhea, pelvic pain) and reduces the size and activity of endometrial implants.
- By inducing a pseudo-menopause state, it creates an environment unfavorable for the growth of ectopic endometrial tissue.
- This is particularly relevant for symptomatic relief in women where fertility is not the primary immediate concern, or as a preoperative/postoperative adjunct.
- 2.
- **Fibrocystic Breast Disease:** Danazol is indicated for the symptomatic treatment of severe, intractable benign fibrocystic breast disease.
- This includes cases characterized by significant pain, tenderness, and nodularity that do not respond to more conservative measures.
- Its action helps to reduce the cyclic mastalgia and nodularity associated with this condition.
- 3.
- **Hereditary Angioedema (HAE):** Danazol is an important therapeutic agent for the prevention of attacks in patients with hereditary angioedema, a rare genetic disorder characterized by recurrent episodes of severe swelling in various body parts.
- It works by increasing the synthesis of C1 esterase inhibitor, a crucial protein involved in regulating the complement and kallikrein-kinin systems, thereby preventing the uncontrolled activation that leads to angioedema attacks.
- This prophylactic use is critical for improving patient quality of life and reducing life-threatening episodes.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Endometriosis: For moderate to severe disease, an initial daily dose of 800 mg given in two divided doses is recommended. Gradual downward titration to a dose sufficient to maintain amenorrhea may be considered based on patient response. For mild cases, an initial daily dose of 200 mg to 400 mg given in two divided doses is recommended and may be adjusted based on patient response. Therapy should begin during menstruation, or appropriate tests should be performed to ensure the patient is not pregnant. Treatment should continue uninterrupted for 3 to 6 months, extendable to 9 months if necessary. If symptoms recur after therapy termination, treatment can be reinstituted. Hereditary Angioedema: Dosage requirements for hereditary angioedema are variable and should be individualized based on patient response. |
Safety & Warnings
Common Side Effects
- Commonly reported adverse effects include nausea, dizziness, and rashes.
- Androgen-like effects such as weight gain, acne, seborrhea, mild hirsutism, edema, hair loss, and voice changes (e.
- g.
- , hoarseness, sore throat, instability or deepening of pitch) may occur and can persist post-therapy.
- Hypertrophy of the clitoris is rare.
- Other endocrine effects include menstrual disturbances (spotting, alteration of cycle timing, amenorrhea), with persistent amenorrhea occasionally reported.
- Flushing, sweating, vaginal dryness and irritation, and reduction in breast size may occur due to lowered estrogen levels.
- Nervousness and emotional lability have been reported.
- In males, a modest reduction in spermatogenesis and abnormalities in semen volume and viscosity may be observed during treatment.
Serious Warnings
- Black Box Warning: Use of danazol in pregnancy is contraindicated. A sensitive test (e.g., beta subunit test if available) capable of determining early pregnancy is recommended immediately prior to start of therapy. Additionally, a non-hormonal method of contraception should be used during therapy. If a patient becomes pregnant while taking danazol, administration of the drug should be discontinued, and the patient should be apprised of the potential risk to the fetus, as exposure to danazol in utero may result in androgenic effects.
- Avoid driving or consuming alcohol while taking this medicine as it may affect your ability to drive.
- Use with extreme caution in patients with severe hepatic, cardiac, or renal dysfunction.
- Prior to initiating therapy, a sensitive test (e.
- g.
- , beta-subunit test) capable of determining early pregnancy is recommended to ensure the patient is not pregnant.
- A non-hormonal method of contraception must be used throughout therapy.
- If a patient becomes pregnant while on danazol, the drug should be immediately discontinued, and the patient must be informed of the potential risk to the fetus (e.
- g.
- , androgenic effects).
How it Works (Mechanism of Action)
Danazol exerts its therapeutic effects through a multifaceted mechanism primarily involving the suppression of gonadotropin secretion and direct hormonal receptor interactions. As a synthetic attenuated androgen, its primary mode of action is the inhibition of pituitary gonadotropin release. It directly suppresses the secretion of both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary gland. This suppression leads to a significant reduction in ovarian steroidogenesis, resulting in decreased circulating levels of estrogen and progesterone. The resulting hypoestrogenic environment is crucial for the treatment of estrogen-dependent conditions like endometriosis and fibrocystic breast disease, as it causes atrophy of ectopic endometrial tissue and reduces breast pain and nodularity.
Beyond its antigonadotropic effects, danazol also exhibits several direct hormonal activities. It possesses weak androgenic, anabolic, and antiestrogenic properties. It can bind to androgen receptors, albeit with lower affinity than endogenous androgens, and can also interact with progesterone and glucocorticoid receptors. Furthermore, danazol directly inhibits several enzymes involved in steroid hormone synthesis, including aromatase (which converts androgens to estrogens) and 3-beta-hydroxysteroid dehydrogenase. This enzymatic inhibition further contributes to the overall reduction in estrogen production.
In the context of hereditary angioedema, danazol's mechanism involves stimulating the synthesis of C1 esterase inhibitor (C1-INH) in the liver. C1-INH is a critical regulator of the complement and kallikrein-kinin systems. By increasing C1-INH levels, danazol helps to restore the balance in these systems, thereby preventing the uncontrolled activation that leads to the excessive production of bradykinin and subsequent angioedema attacks. This unique action makes it an effective prophylactic agent for HAE.